Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $2.40

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $2.40, but opened at $2.75. Taysha Gene Therapies shares last traded at $2.71, with a volume of 555,839 shares changing hands.

Analysts Set New Price Targets

TSHA has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, April 30th. Canaccord Genuity Group reiterated a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Piper Sandler initiated coverage on Taysha Gene Therapies in a research report on Tuesday, April 9th. They issued an "overweight" rating and a $9.00 price target on the stock. JMP Securities restated a "market outperform" rating and set a $5.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, March 20th. Finally, Jefferies Financial Group restated a "buy" rating and set a $8.00 price objective (up from $2.00) on shares of Taysha Gene Therapies in a research note on Tuesday. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $7.00.

Taysha Gene Therapies Stock Performance

The firm has a market capitalization of $480.64 million, a P/E ratio of -4.01 and a beta of 0.37. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.08 and a quick ratio of 4.08. The firm has a 50-day moving average price of $2.61 and a two-hundred day moving average price of $2.10.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share for the quarter. The firm had revenue of $3.60 million during the quarter, compared to analysts' expectations of $4.75 million. On average, analysts forecast that Taysha Gene Therapies, Inc. will post -0.39 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Howard Capital Management Inc. acquired a new position in Taysha Gene Therapies during the fourth quarter worth $25,000. Victory Capital Management Inc. acquired a new position in Taysha Gene Therapies in the 4th quarter valued at about $28,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Taysha Gene Therapies in the 4th quarter valued at approximately $31,000. Lee Financial Co purchased a new position in shares of Taysha Gene Therapies during the 3rd quarter worth $63,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Taysha Gene Therapies in the 4th quarter valued at about $38,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.